Powerpoint presentation by dr sathiha
•Download as PPT, PDF•
1 like•779 views
This study compared the effectiveness of two chemotherapy regimens, BEACOPP and COPP-ABVD, for treating advanced Hodgkin's lymphoma. 49 patients received either BEACOPP (25 patients) or COPP-ABVD (24 patients). The rate of freedom from treatment failure at 5 years was higher for BEACOPP at 76% compared to 69% for COPP-ABVD. Overall survival rates at 5 years were also higher for BEACOPP at 88% versus 83% for COPP-ABVD. While BEACOPP resulted in better tumor control and survival, it also had more acute toxicity including grade 4 leukopenia in some cycles.
Report
Share
Report
Share
![Introduction ,[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
ASCO-2016 Update Non-Hodgkin’s Lymphoma & Myeloma
The document discusses results from several clinical trials related to lymphoma. The MAINTAIN trial found no significant difference in progression-free survival between the rituximab maintenance and observation arms for patients with mantle cell lymphoma. The E2408 phase II trial found that adding bortezomib to R-CHOP improved the complete response rate for patients with high-risk follicular lymphoma compared to R-CHOP alone. A trial of a "sandwich-like" GDP chemotherapy regimen with radiotherapy for nasopharyngeal NK/T-cell lymphoma reported a complete response rate of 81.9% after full treatment and 2-year overall and progression-free survival rates of 84.6% and 81.6%,
Rare Solid Cancers: An Introduction - Slide 13 - R. Soffietti - Rare CNS canc...
Rare Solid Cancers: An Introduction - Slide 13 - R. Soffietti - Rare CNS canc...European School of Oncology
This document summarizes a presentation on rare central nervous system (CNS) cancers. It discusses molecular markers in gliomas, treatment with antiangiogenic drugs like bevacizumab, and management of low-grade tumors. It also reviews studies on chemotherapy for recurrent and newly diagnosed low-grade gliomas, ongoing clinical trials, and risks of distant spread with bevacizumab treatment.Breast cancer quiz (For Radiation Oncology residents)
1. The document outlines the rules and structure of a breast cancer quiz with 4 rounds: a visual round, multiple choice round, clinical trial identification round, and true/false round.
2. The visual round involves identifying devices, images, and celebrities related to breast cancer. The multiple choice round contains questions about breast cancer criteria, definitions, and screening recommendations.
3. The clinical trial round tasks teams with naming clinical trials from descriptions of trial details. The true/false round presents statements about breast cancer topics like DCIS, male breast cancer, and Mammaprint to identify as true or false.
ASH 2015 NHL clinical update
This is NHL clinical update on 57th ASH Annual Meeting and Exposition (December 5-8, 2015).
It includes only clinical aspects include both chemotherapy and antibody therapy.
ASCO 2015 Lymphoma update
1) A phase 2 trial found that lenalidomide plus rituximab was effective for treating relapsed or refractory mantle cell lymphoma, with an overall response rate of 56.5% and durable responses over 20 months.
2) A phase 1/2 trial found that brentuximab vedotin combined with R-CHOP led to high response rates in frontline treatment of high-intermediate/high-risk diffuse large B-cell lymphoma, including a complete response rate of 92% in CD30-positive patients.
3) A study found that a pre-phase of prednisone and rituximab helped mitigate early toxicity for older diffuse large B-cell lymphoma patients
Rcc in 2021
This document outlines the treatment of advanced/metastatic renal cell carcinoma (RCC). It discusses that nephrectomy may still have a role in metastatic RCC for some patients. Active surveillance is an option for favorable risk metastatic RCC patients. Several trials found no differences between tyrosine kinase inhibitors as first line options for metastatic RCC. Second line options after progression on TKIs include mTOR inhibitors, VEGF inhibitors, and immune checkpoint inhibitors. Recent data supports immune checkpoint inhibitors like nivolumab plus ipilimumab as the new standard of care for first line treatment of metastatic RCC based on improved overall survival compared to sunitinib in clinical trials.
Update on Systemic Therapy for Metastatic Pancreas Adenocarcinoma
The document discusses treatment options for metastatic pancreatic cancer. For first-line therapy, FOLFIRINOX is an option but is reserved for younger, healthier patients due to toxicity. Gemcitabine plus nab-paclitaxel is a preferred first-line option. For second-line therapy after progression on gemcitabine, nanoliposomal irinotecan plus 5-FU/LV has shown a survival benefit compared to 5-FU/LV alone. Molecular profiling of pancreatic tumors has identified subtypes that could help guide targeted therapies, and immune-based approaches also offer promise. The James Cancer Hospital is conducting clinical trials evaluating novel combinations for both first-line and second-line metastatic pancreatic cancer
Tumor board
This document summarizes a tumor board discussion of a case involving a 21-year-old patient presenting with loose stools and abdominal pain for 2 months. Key details include KRAS mutation testing of the patient's tumor sample, which showed no mutation. The discussion covers epidemiology of early-onset colorectal cancer in India, treatment options including chemotherapy and targeted therapies, and factors influencing first-line treatment decisions for metastatic colorectal cancer such as biomarker status and primary tumor location.
Recommended
ASCO-2016 Update Non-Hodgkin’s Lymphoma & Myeloma
The document discusses results from several clinical trials related to lymphoma. The MAINTAIN trial found no significant difference in progression-free survival between the rituximab maintenance and observation arms for patients with mantle cell lymphoma. The E2408 phase II trial found that adding bortezomib to R-CHOP improved the complete response rate for patients with high-risk follicular lymphoma compared to R-CHOP alone. A trial of a "sandwich-like" GDP chemotherapy regimen with radiotherapy for nasopharyngeal NK/T-cell lymphoma reported a complete response rate of 81.9% after full treatment and 2-year overall and progression-free survival rates of 84.6% and 81.6%,
Rare Solid Cancers: An Introduction - Slide 13 - R. Soffietti - Rare CNS canc...
Rare Solid Cancers: An Introduction - Slide 13 - R. Soffietti - Rare CNS canc...European School of Oncology
This document summarizes a presentation on rare central nervous system (CNS) cancers. It discusses molecular markers in gliomas, treatment with antiangiogenic drugs like bevacizumab, and management of low-grade tumors. It also reviews studies on chemotherapy for recurrent and newly diagnosed low-grade gliomas, ongoing clinical trials, and risks of distant spread with bevacizumab treatment.Breast cancer quiz (For Radiation Oncology residents)
1. The document outlines the rules and structure of a breast cancer quiz with 4 rounds: a visual round, multiple choice round, clinical trial identification round, and true/false round.
2. The visual round involves identifying devices, images, and celebrities related to breast cancer. The multiple choice round contains questions about breast cancer criteria, definitions, and screening recommendations.
3. The clinical trial round tasks teams with naming clinical trials from descriptions of trial details. The true/false round presents statements about breast cancer topics like DCIS, male breast cancer, and Mammaprint to identify as true or false.
ASH 2015 NHL clinical update
This is NHL clinical update on 57th ASH Annual Meeting and Exposition (December 5-8, 2015).
It includes only clinical aspects include both chemotherapy and antibody therapy.
ASCO 2015 Lymphoma update
1) A phase 2 trial found that lenalidomide plus rituximab was effective for treating relapsed or refractory mantle cell lymphoma, with an overall response rate of 56.5% and durable responses over 20 months.
2) A phase 1/2 trial found that brentuximab vedotin combined with R-CHOP led to high response rates in frontline treatment of high-intermediate/high-risk diffuse large B-cell lymphoma, including a complete response rate of 92% in CD30-positive patients.
3) A study found that a pre-phase of prednisone and rituximab helped mitigate early toxicity for older diffuse large B-cell lymphoma patients
Rcc in 2021
This document outlines the treatment of advanced/metastatic renal cell carcinoma (RCC). It discusses that nephrectomy may still have a role in metastatic RCC for some patients. Active surveillance is an option for favorable risk metastatic RCC patients. Several trials found no differences between tyrosine kinase inhibitors as first line options for metastatic RCC. Second line options after progression on TKIs include mTOR inhibitors, VEGF inhibitors, and immune checkpoint inhibitors. Recent data supports immune checkpoint inhibitors like nivolumab plus ipilimumab as the new standard of care for first line treatment of metastatic RCC based on improved overall survival compared to sunitinib in clinical trials.
Update on Systemic Therapy for Metastatic Pancreas Adenocarcinoma
The document discusses treatment options for metastatic pancreatic cancer. For first-line therapy, FOLFIRINOX is an option but is reserved for younger, healthier patients due to toxicity. Gemcitabine plus nab-paclitaxel is a preferred first-line option. For second-line therapy after progression on gemcitabine, nanoliposomal irinotecan plus 5-FU/LV has shown a survival benefit compared to 5-FU/LV alone. Molecular profiling of pancreatic tumors has identified subtypes that could help guide targeted therapies, and immune-based approaches also offer promise. The James Cancer Hospital is conducting clinical trials evaluating novel combinations for both first-line and second-line metastatic pancreatic cancer
Tumor board
This document summarizes a tumor board discussion of a case involving a 21-year-old patient presenting with loose stools and abdominal pain for 2 months. Key details include KRAS mutation testing of the patient's tumor sample, which showed no mutation. The discussion covers epidemiology of early-onset colorectal cancer in India, treatment options including chemotherapy and targeted therapies, and factors influencing first-line treatment decisions for metastatic colorectal cancer such as biomarker status and primary tumor location.
Slide deck updates on cml (1)
Dasatinib is an effective first-line treatment for chronic myeloid leukemia (CML) based on results from the DASISION trial. The trial showed that dasatinib induced higher and faster rates of complete cytogenetic response and major molecular response compared to imatinib. At 5 years of follow-up, dasatinib maintained superior rates of molecular responses including deeper responses below 0.1% BCR-ABL1. Dasatinib therefore provides improved long-term outcomes for patients with newly diagnosed CML compared to standard imatinib treatment.
ASCO 2016 Thoracic Review
1) The document summarizes results from several studies presented at the 2016 ASCO conference related to thoracic cancers.
2) A study of adjuvant chemotherapy regimens for non-small cell lung cancer found no difference in outcomes between regimens containing vinorelbine, docetaxel, gemcitabine, or pemetrexed. Pemetrexed had less toxicity.
3) A trial of twice-daily vs once-daily radiation therapy for limited stage small cell lung cancer found no difference in overall survival between the arms.
FOLLICULAR LYMPHOMA; UPDATES ON TREATMENT STRATEGIES
This document discusses treatment strategies for follicular lymphoma. It begins by outlining options for limited versus advanced stage disease, including watch and wait for asymptomatic low tumor burden or chemotherapy/immunotherapy for symptomatic high tumor burden. Key clinical questions are presented regarding the role of watch and wait in the rituximab era and optimal frontline therapies. Several studies comparing rituximab combined with different chemotherapy regimens are summarized, with one finding superior outcomes for R-CHOP compared to R-CVP or R-FM. Data is also presented showing superior progression-free and overall survival for bendamustine-rituximab compared to CHOP-rituximab. Toxicity profiles also favor bend
Controversies in hepato-biliary surgery
This document summarizes a presentation on controversies in hepatobiliary pancreatic surgery. It discusses 4 topics: 1) Whether resectable hilar cholangiocarcinoma should be resected or treated with orthotopic liver transplantation, 2) How to treat node-positive intrahepatic cholangiocarcinoma, 3) Options for unresectable intrahepatic cholangiocarcinoma, and 4) Managing large hepatocellular carcinoma in early cirrhosis. For each topic, one or more case examples are described and various treatment approaches are outlined and discussed. Supporting data from studies on outcomes with different strategies are also presented.
Optimal treatment sequence left side ras wt - case based (1)
1. The document discusses optimal treatment sequence for left side RAS wild-type and BRAF wild-type metastatic colorectal cancer (mCRC).
2. It describes four groups of patients with metastatic disease based on resectability and provides treatment goals for each. Most patients initially present with unresectable disease.
3. Factors that influence first-line treatment choices for mCRC include biomarker status, tumor location, treatment sequence, and patient characteristics. Molecular testing for RAS and BRAF is recommended to guide treatment decisions.
Evolving Management of Follicular Lymphoma
Evolving Management of Follicular LymphomaJohn Theurer Cancer Center at Hackensack University Medical Center
Myron Czuczman, M.D., Professor Chief, Lymphoma/Myeloma Service, Dept. of Medicine Head, Lymphoma Translational Research Laboratory Dept. of Immunology Roswell Park Cancer Center
Evolving Management of Follicular Lymphoma
Presented at New Frontiers in the Management of Solid and Liquid Tumors hosted by the John Theurer Cancer Center at Hackensack University Medical Center. jtcancercenter.org/CMEASH 2014 update in lymphoma
The study evaluated 155 patients with T-cell lymphoblastic lymphoma treated with a pediatric-inspired ALL protocol. 91% of patients achieved a complete or unconfirmed response. With a median follow-up of 5.9 years, the 5-year disease-free survival was 71%, event-free survival was 61%, and overall survival was 66%. High serum LDH levels were associated with decreased event-free and overall survival. A 4-gene risk classifier identified patients with a high-risk genetic profile who had significantly shorter event-free, disease-free, and overall survival.
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...
Ponencia en el primer simposio de la Asociación Colombiana de Hematología y Oncología (ACHO) de cáncer genitourinario, Bogotá, septiembre 23 y 24 de 2016.
Terapia sistémica en cáncer de testículo
The document discusses treatment options for testicular cancer, including surveillance, radiotherapy, carboplatin chemotherapy, and cisplatin-based chemotherapy. It provides details on clinical trials comparing radiotherapy and carboplatin for stage I seminoma, and evaluates outcomes and toxicities. The document also reviews management of advanced or metastatic testicular cancer with carboplatin or cisplatin-based regimens along with the role of PET scanning in response assessment.
S. Cascinu - Liver/Hepatobiliary - State of the art
- The document discusses liver and hepatobiliary cancers, focusing on hepatocellular carcinoma (HCC). It covers the epidemiology, risk factors, screening and diagnosis of HCC as well as staging systems and treatment options.
- Risk factors for HCC include hepatitis B and C infection, alcohol consumption, and aflatoxin intake. Screening ultrasound and AFP tests are used for early diagnosis in high-risk patients. The BCLC staging system guides treatment which includes resection, transplantation, ablation, and embolization.
- For intermediate stage HCC, transarterial chemoembolization provides the best outcomes, with 70-80% of patients surviving 1 year and 50% surviving 3 years. However
A. Stathis - New drugs in the treatment of lymphomas
The document summarizes highlights from the 11-ICML Lugano conference in 2011, including:
1) Studies showing the impact of the tumor microenvironment in lymphoma prognosis and the predictive value of increased macrophages in Hodgkin's lymphoma biopsies.
2) High response rates to antiviral treatment in patients with indolent B-cell lymphoma associated with HCV infection.
3) A PET-based approach can effectively guide treatment for limited-stage diffuse large B-cell lymphoma.
4) R-CHOP induction followed by rituximab maintenance improves survival over R-FC induction for elderly patients with mantle cell lymphoma.
Antiangiogenic Therapy in colorectal cancer
1) Anti-angiogenic therapy targets tumor angiogenesis and has become an established treatment for metastatic colorectal cancer (mCRC).
2) Bevacizumab, a monoclonal antibody targeting VEGF, has shown efficacy in multiple phase III trials in combination with chemotherapy as first-line and maintenance therapy for mCRC.
3) Additional anti-angiogenic agents approved for mCRC include aflibercept, ramucirumab, and regorafinib, which have demonstrated benefits in later lines of therapy.
Dabrafenib Journal Club
Dabrafenib was compared to dacarbazine for treatment of metastatic melanoma with BRAF V600E mutation in a randomized phase 3 clinical trial. The trial found that dabrafenib significantly improved progression-free survival over dacarbazine, with a median of 5.1 months for dabrafenib versus 2.7 months for dacarbazine. Dabrafenib also had a higher objective response rate. Common adverse events for dabrafenib included hyperkeratosis and palmar-plantar erythrodysesthesia. The study demonstrated that dabrafenib is an effective treatment option for metastatic melanoma patients with BRAF mutation.
V_Hematology_Forum_Dr_Pavithran
This document summarizes prognostic factors and treatment approaches for follicular lymphoma. Some key points:
- Prognostic factors include age, histologic grade, FLIPI score, gene expression profiling, and metabolic tumor volume on PET scans.
- First-line treatment for symptomatic advanced disease is usually rituximab plus chemotherapy such as bendamustine, followed by rituximab maintenance for 2 years.
- The PRIMA trial showed improved progression-free survival with 2 years of rituximab maintenance compared to observation alone in patients achieving response to first-line treatment.
- The GALLIUM trial found improved progression-free survival for first-line treatment of follicular
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Fight Colorectal Cancer
This document summarizes key findings from the PRIME trial evaluating the addition of panitumumab to FOLFOX4 as first-line treatment for metastatic colorectal cancer. Biomarker analysis found that KRAS exon 2 wild-type tumors derived greater benefit from the addition of panitumumab, with a progression-free survival advantage compared to FOLFOX4 alone. Further biomarker testing found mutations in other RAS isoforms or BRAF reduced likelihood of benefit from panitumumab. The results support use of RAS/BRAF mutation testing to select patients for first-line anti-EGFR therapy in combination with chemotherapy.LLA 2011 - J.M. Connors - Problems of the design and interpretation of phase ...
LLA 2011 - J.M. Connors - Problems of the design and interpretation of phase ...European School of Oncology
This document discusses challenges in interpreting data from phase II and III clinical trials. It notes that generalizability can be limited by a shifting denominator as patient characteristics change over time. It also discusses that reduced treatment intensity does not necessarily mean less effective treatment if higher intensity results in better drug exposure and outcomes for patients. Stage migration and lead time bias can also impact interpretation as detection of earlier stage disease improves over time.R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)European School of Oncology
The document provides guidelines for the treatment of advanced non-small cell lung cancer. It recommends that first-line therapy should consist of platinum-based combination chemotherapy for patients with good performance status. For patients with EGFR mutations, an EGFR tyrosine kinase inhibitor is the preferred first-line treatment. It also recommends the addition of bevacizumab or cetuximab to platinum-based chemotherapy for certain patients.J.B. Vermorken - Ovarian cancer - State of the art
This document summarizes key information about ovarian cancer, including epidemiology, staging, treatment milestones, prognostic factors, and recent clinical trials. It notes that the median age of diagnosis is 63 years and discusses improvements in 5-year survival over time. New developments discussed include the role of surgery, chemotherapy regimens, targeted therapies like bevacizumab, and trials in recurrent settings.
Mundipharma asyut cancer center-2018
management of chemotherapy induced nausea and vomiting as an integral part of cancer management and not palliative talking
METASTATC COLORECTAL CANCER IN 2017
This document summarizes a presentation on the management of metastatic colorectal cancer (mCRC) in 2017. It discusses several key points:
1) Patient stratification is important in determining treatment approach for mCRC, taking into account factors like disease extent and symptoms.
2) A multidisciplinary team approach is mandatory for developing optimal treatment plans.
3) Assessment of predictive biomarkers like RAS mutations helps determine which first-line treatments may be most effective.
4) Tumor location (right vs left-sided colon cancer) can impact treatment outcomes and response to certain drugs like anti-EGFR therapies.
5) Multiple clinical trials over time have led to improved survival outcomes and more
Hodgkin’S And Non Hodgkin’S Lymphoma
This document summarizes information about Hodgkin's and non-Hodgkin's lymphoma, including:
- Hodgkin's lymphoma accounts for about 30% of malignant lymphomas and is typically treated initially with ABVD chemotherapy plus radiation therapy. Non-Hodgkin's lymphoma is more common and heterogeneous.
- For advanced Hodgkin's lymphoma, BEACOPP chemotherapy is more effective than COPP/ABVD but also more toxic, increasing risks of infertility, premature menopause, and leukemia.
- Long-term survivors of Hodgkin's lymphoma face elevated risks of secondary cancers decades later due to effects of treatment.
DLBCL- Recent Molecular Classification.pptx
diffuse large B cell lymphoma recent molecular classification
molecular classification and their time frame with references
Recent advantages of DLBCL and thier implication in therapy
More Related Content
What's hot
Slide deck updates on cml (1)
Dasatinib is an effective first-line treatment for chronic myeloid leukemia (CML) based on results from the DASISION trial. The trial showed that dasatinib induced higher and faster rates of complete cytogenetic response and major molecular response compared to imatinib. At 5 years of follow-up, dasatinib maintained superior rates of molecular responses including deeper responses below 0.1% BCR-ABL1. Dasatinib therefore provides improved long-term outcomes for patients with newly diagnosed CML compared to standard imatinib treatment.
ASCO 2016 Thoracic Review
1) The document summarizes results from several studies presented at the 2016 ASCO conference related to thoracic cancers.
2) A study of adjuvant chemotherapy regimens for non-small cell lung cancer found no difference in outcomes between regimens containing vinorelbine, docetaxel, gemcitabine, or pemetrexed. Pemetrexed had less toxicity.
3) A trial of twice-daily vs once-daily radiation therapy for limited stage small cell lung cancer found no difference in overall survival between the arms.
FOLLICULAR LYMPHOMA; UPDATES ON TREATMENT STRATEGIES
This document discusses treatment strategies for follicular lymphoma. It begins by outlining options for limited versus advanced stage disease, including watch and wait for asymptomatic low tumor burden or chemotherapy/immunotherapy for symptomatic high tumor burden. Key clinical questions are presented regarding the role of watch and wait in the rituximab era and optimal frontline therapies. Several studies comparing rituximab combined with different chemotherapy regimens are summarized, with one finding superior outcomes for R-CHOP compared to R-CVP or R-FM. Data is also presented showing superior progression-free and overall survival for bendamustine-rituximab compared to CHOP-rituximab. Toxicity profiles also favor bend
Controversies in hepato-biliary surgery
This document summarizes a presentation on controversies in hepatobiliary pancreatic surgery. It discusses 4 topics: 1) Whether resectable hilar cholangiocarcinoma should be resected or treated with orthotopic liver transplantation, 2) How to treat node-positive intrahepatic cholangiocarcinoma, 3) Options for unresectable intrahepatic cholangiocarcinoma, and 4) Managing large hepatocellular carcinoma in early cirrhosis. For each topic, one or more case examples are described and various treatment approaches are outlined and discussed. Supporting data from studies on outcomes with different strategies are also presented.
Optimal treatment sequence left side ras wt - case based (1)
1. The document discusses optimal treatment sequence for left side RAS wild-type and BRAF wild-type metastatic colorectal cancer (mCRC).
2. It describes four groups of patients with metastatic disease based on resectability and provides treatment goals for each. Most patients initially present with unresectable disease.
3. Factors that influence first-line treatment choices for mCRC include biomarker status, tumor location, treatment sequence, and patient characteristics. Molecular testing for RAS and BRAF is recommended to guide treatment decisions.
Evolving Management of Follicular Lymphoma
Evolving Management of Follicular LymphomaJohn Theurer Cancer Center at Hackensack University Medical Center
Myron Czuczman, M.D., Professor Chief, Lymphoma/Myeloma Service, Dept. of Medicine Head, Lymphoma Translational Research Laboratory Dept. of Immunology Roswell Park Cancer Center
Evolving Management of Follicular Lymphoma
Presented at New Frontiers in the Management of Solid and Liquid Tumors hosted by the John Theurer Cancer Center at Hackensack University Medical Center. jtcancercenter.org/CMEASH 2014 update in lymphoma
The study evaluated 155 patients with T-cell lymphoblastic lymphoma treated with a pediatric-inspired ALL protocol. 91% of patients achieved a complete or unconfirmed response. With a median follow-up of 5.9 years, the 5-year disease-free survival was 71%, event-free survival was 61%, and overall survival was 66%. High serum LDH levels were associated with decreased event-free and overall survival. A 4-gene risk classifier identified patients with a high-risk genetic profile who had significantly shorter event-free, disease-free, and overall survival.
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...
Ponencia en el primer simposio de la Asociación Colombiana de Hematología y Oncología (ACHO) de cáncer genitourinario, Bogotá, septiembre 23 y 24 de 2016.
Terapia sistémica en cáncer de testículo
The document discusses treatment options for testicular cancer, including surveillance, radiotherapy, carboplatin chemotherapy, and cisplatin-based chemotherapy. It provides details on clinical trials comparing radiotherapy and carboplatin for stage I seminoma, and evaluates outcomes and toxicities. The document also reviews management of advanced or metastatic testicular cancer with carboplatin or cisplatin-based regimens along with the role of PET scanning in response assessment.
S. Cascinu - Liver/Hepatobiliary - State of the art
- The document discusses liver and hepatobiliary cancers, focusing on hepatocellular carcinoma (HCC). It covers the epidemiology, risk factors, screening and diagnosis of HCC as well as staging systems and treatment options.
- Risk factors for HCC include hepatitis B and C infection, alcohol consumption, and aflatoxin intake. Screening ultrasound and AFP tests are used for early diagnosis in high-risk patients. The BCLC staging system guides treatment which includes resection, transplantation, ablation, and embolization.
- For intermediate stage HCC, transarterial chemoembolization provides the best outcomes, with 70-80% of patients surviving 1 year and 50% surviving 3 years. However
A. Stathis - New drugs in the treatment of lymphomas
The document summarizes highlights from the 11-ICML Lugano conference in 2011, including:
1) Studies showing the impact of the tumor microenvironment in lymphoma prognosis and the predictive value of increased macrophages in Hodgkin's lymphoma biopsies.
2) High response rates to antiviral treatment in patients with indolent B-cell lymphoma associated with HCV infection.
3) A PET-based approach can effectively guide treatment for limited-stage diffuse large B-cell lymphoma.
4) R-CHOP induction followed by rituximab maintenance improves survival over R-FC induction for elderly patients with mantle cell lymphoma.
Antiangiogenic Therapy in colorectal cancer
1) Anti-angiogenic therapy targets tumor angiogenesis and has become an established treatment for metastatic colorectal cancer (mCRC).
2) Bevacizumab, a monoclonal antibody targeting VEGF, has shown efficacy in multiple phase III trials in combination with chemotherapy as first-line and maintenance therapy for mCRC.
3) Additional anti-angiogenic agents approved for mCRC include aflibercept, ramucirumab, and regorafinib, which have demonstrated benefits in later lines of therapy.
Dabrafenib Journal Club
Dabrafenib was compared to dacarbazine for treatment of metastatic melanoma with BRAF V600E mutation in a randomized phase 3 clinical trial. The trial found that dabrafenib significantly improved progression-free survival over dacarbazine, with a median of 5.1 months for dabrafenib versus 2.7 months for dacarbazine. Dabrafenib also had a higher objective response rate. Common adverse events for dabrafenib included hyperkeratosis and palmar-plantar erythrodysesthesia. The study demonstrated that dabrafenib is an effective treatment option for metastatic melanoma patients with BRAF mutation.
V_Hematology_Forum_Dr_Pavithran
This document summarizes prognostic factors and treatment approaches for follicular lymphoma. Some key points:
- Prognostic factors include age, histologic grade, FLIPI score, gene expression profiling, and metabolic tumor volume on PET scans.
- First-line treatment for symptomatic advanced disease is usually rituximab plus chemotherapy such as bendamustine, followed by rituximab maintenance for 2 years.
- The PRIMA trial showed improved progression-free survival with 2 years of rituximab maintenance compared to observation alone in patients achieving response to first-line treatment.
- The GALLIUM trial found improved progression-free survival for first-line treatment of follicular
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Fight Colorectal Cancer
This document summarizes key findings from the PRIME trial evaluating the addition of panitumumab to FOLFOX4 as first-line treatment for metastatic colorectal cancer. Biomarker analysis found that KRAS exon 2 wild-type tumors derived greater benefit from the addition of panitumumab, with a progression-free survival advantage compared to FOLFOX4 alone. Further biomarker testing found mutations in other RAS isoforms or BRAF reduced likelihood of benefit from panitumumab. The results support use of RAS/BRAF mutation testing to select patients for first-line anti-EGFR therapy in combination with chemotherapy.LLA 2011 - J.M. Connors - Problems of the design and interpretation of phase ...
LLA 2011 - J.M. Connors - Problems of the design and interpretation of phase ...European School of Oncology
This document discusses challenges in interpreting data from phase II and III clinical trials. It notes that generalizability can be limited by a shifting denominator as patient characteristics change over time. It also discusses that reduced treatment intensity does not necessarily mean less effective treatment if higher intensity results in better drug exposure and outcomes for patients. Stage migration and lead time bias can also impact interpretation as detection of earlier stage disease improves over time.R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)European School of Oncology
The document provides guidelines for the treatment of advanced non-small cell lung cancer. It recommends that first-line therapy should consist of platinum-based combination chemotherapy for patients with good performance status. For patients with EGFR mutations, an EGFR tyrosine kinase inhibitor is the preferred first-line treatment. It also recommends the addition of bevacizumab or cetuximab to platinum-based chemotherapy for certain patients.J.B. Vermorken - Ovarian cancer - State of the art
This document summarizes key information about ovarian cancer, including epidemiology, staging, treatment milestones, prognostic factors, and recent clinical trials. It notes that the median age of diagnosis is 63 years and discusses improvements in 5-year survival over time. New developments discussed include the role of surgery, chemotherapy regimens, targeted therapies like bevacizumab, and trials in recurrent settings.
Mundipharma asyut cancer center-2018
management of chemotherapy induced nausea and vomiting as an integral part of cancer management and not palliative talking
METASTATC COLORECTAL CANCER IN 2017
This document summarizes a presentation on the management of metastatic colorectal cancer (mCRC) in 2017. It discusses several key points:
1) Patient stratification is important in determining treatment approach for mCRC, taking into account factors like disease extent and symptoms.
2) A multidisciplinary team approach is mandatory for developing optimal treatment plans.
3) Assessment of predictive biomarkers like RAS mutations helps determine which first-line treatments may be most effective.
4) Tumor location (right vs left-sided colon cancer) can impact treatment outcomes and response to certain drugs like anti-EGFR therapies.
5) Multiple clinical trials over time have led to improved survival outcomes and more
What's hot (20)
FOLLICULAR LYMPHOMA; UPDATES ON TREATMENT STRATEGIES
FOLLICULAR LYMPHOMA; UPDATES ON TREATMENT STRATEGIES
Optimal treatment sequence left side ras wt - case based (1)
Optimal treatment sequence left side ras wt - case based (1)
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
LLA 2011 - J.M. Connors - Problems of the design and interpretation of phase ...
LLA 2011 - J.M. Connors - Problems of the design and interpretation of phase ...
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
Similar to Powerpoint presentation by dr sathiha
Hodgkin’S And Non Hodgkin’S Lymphoma
This document summarizes information about Hodgkin's and non-Hodgkin's lymphoma, including:
- Hodgkin's lymphoma accounts for about 30% of malignant lymphomas and is typically treated initially with ABVD chemotherapy plus radiation therapy. Non-Hodgkin's lymphoma is more common and heterogeneous.
- For advanced Hodgkin's lymphoma, BEACOPP chemotherapy is more effective than COPP/ABVD but also more toxic, increasing risks of infertility, premature menopause, and leukemia.
- Long-term survivors of Hodgkin's lymphoma face elevated risks of secondary cancers decades later due to effects of treatment.
DLBCL- Recent Molecular Classification.pptx
diffuse large B cell lymphoma recent molecular classification
molecular classification and their time frame with references
Recent advantages of DLBCL and thier implication in therapy
Hodgkin chemo final
This document summarizes the use of PET-CT in staging and assessing treatment response in Hodgkin's lymphoma. It discusses that PET-CT is an important tool for initial staging, assessing response to chemotherapy, and prognostic indicator when done after partial chemotherapy. The sensitivity and specificity of PET-CT is higher than CT alone for detecting nodal and organ involvement. PET-CT may avoid the need for bone marrow biopsy in some cases. Interim PET imaging helps distinguish residual mass as viable tumor or necrosis/fibrosis. The document also reviews chemotherapy regimens like ABVD, BEACOPP and Stanford V in early and advanced Hodgkin's lymphoma.
Bendamustine Vs R-CHOP/R-CVP-Bright study
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
hodkins ppt.ppt
Hodgkin lymphoma is one of the most curable cancers in children. It can be effectively treated with chemotherapy alone or chemotherapy with limited radiation, allowing many patients to be cured while avoiding long term side effects of treatment. A study in Karachi, Pakistan found that using alternating chemotherapy regimens without widespread radiation achieved a 3-year overall survival rate of 98% and event-free survival of 92% for children with Hodgkin lymphoma.
Chan myae htut
The document presents findings from a study comparing CHOP chemotherapy alone versus CHOP plus rituximab in elderly patients with diffuse large B cell lymphoma. The study found that adding rituximab to CHOP chemotherapy significantly increased complete response rates, decreased treatment failure and relapse rates, and improved event-free and overall survival compared to CHOP alone, without significantly increasing toxicity.
02 ptcl ylk
This document summarizes advances in the treatment of T cell lymphomas. It discusses that T cell lymphomas are a heterogeneous group that require different treatment strategies. Autologous stem cell transplantation improves outcomes for patients who achieve complete remission. Allogeneic stem cell transplantation may provide long-term remissions for nodal T cell lymphomas but has higher non-relapse mortality. Novel agents like romidepsin and bendamustine show promising response rates in relapsed/refractory disease. Overall, stem cell transplantation improves survival when given in the frontline or chemotherapy-sensitive setting, but optimal primary chemotherapy regimens need further refinement to get more patients to transplant.
Yehlaingbwar
This document summarizes a study on prognostic factors for epithelial ovarian cancer. The study analyzed 55 patients treated with surgery and chemotherapy between 2005-2009. Key findings included:
1) Significant prognostic factors in univariate analysis were age, histology, FIGO stage, and ascites.
2) Patients aged 70 or older and with FIGO stage IV cancer had poorer prognoses, with a 31-month survival time.
3) Patients with endometrioid or clear cell histology had longer survival times at 51 months.
Yehlaingbwar
This document summarizes a study on prognostic factors for epithelial ovarian cancer. The study analyzed 55 patients treated with surgery and chemotherapy between 2005-2009. Key findings included:
1) Significant prognostic factors in univariate analysis were age, histology, FIGO stage, and ascites.
2) Patients aged 70 or older and with FIGO stage IV cancer had poorer prognoses, with a 31-month survival time.
3) Patients with endometrioid or clear cell histology had longer survival times at 51 months.
Yehlaingbwar
This document discusses prognostic factors in epithelial ovarian cancer. It analyzes data from 55 patients treated with primary surgery and chemotherapy between 2005-2009. The key findings are:
1. Significant prognostic factors in univariate analysis included age, histology, FIGO stage, and ascites.
2. Patients aged 70 or older and with FIGO stage IV cancer had poorer prognoses, with a 31-month survival time. Patients with endometrioid or clear cell histology had longer survival, at 51 months.
3. Subgroups like endometrioid/clear cell histology, FIGO stage II, and those with ascites were also significant prognostic factors in univariate analysis.
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Hepatocellul...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Hepatocellul...European School of Oncology
This document discusses hepatocellular carcinoma and treatment with sorafenib. It summarizes a clinical trial that found sorafenib prolonged overall survival compared to placebo in patients with advanced hepatocellular carcinoma. The median overall survival was 46 weeks for sorafenib versus 34 weeks for placebo, representing a 44% increase in survival time. Sorafenib also prolonged time to progression compared to placebo. Based on these results, sorafenib became the first systemic therapy to prolong survival for hepatocellular carcinoma patients.Antibiotic prophylaxis in sever Acute Panceriatitis
This document summarizes a systematic review and meta-analysis of randomized controlled trials examining whether antibiotic prophylaxis is protective in severe acute pancreatitis. The review included 502 patients from studies comparing antibiotic prophylaxis to placebo. The meta-analysis found no significant difference in mortality between the antibiotic and placebo groups, with a relative risk of 0.76. Sensitivity analyses also found no benefit of antibiotics on outcomes like infected necrosis, surgical interventions, or mortality in higher quality studies. The only benefit seen was a reduction in non-pancreatic infections with antibiotics.
V_Hematology_Forum_B_Afanasiev
This document summarizes the use of allo-HSCT and immunotherapy in the treatment of relapsed or refractory classical Hodgkin lymphoma. It provides statistics on Hodgkin lymphoma incidence and outcomes with first-line therapy in Russia. It then discusses the role and indications for allo-HSCT versus auto-HSCT based on guidelines. The document also reviews outcomes from different conditioning regimens and GVHD prophylaxis for allo-HSCT. It summarizes the efficacy of novel immunotherapies like brentuximab vedotin and PD-1 inhibitors for relapsed disease, including as bridge therapy to allo-HSCT. Finally, it discusses treatment options for post-transplant relapse including donor lymph
Immunotherapy update
This document summarizes key findings from a clinical trial comparing the combination of nivolumab and ipilimumab to nivolumab or ipilimumab alone as treatment for previously untreated unresectable or metastatic melanoma. The combination of nivolumab and ipilimumab showed improved progression-free and overall survival compared to either agent alone. The combination also demonstrated a higher objective response rate, particularly in patients with PD-L1 expression levels of 5% or higher. Treatment-related adverse events were more common with the combination but most were manageable.
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...European School of Oncology
This document discusses challenges in the design and interpretation of early phase clinical trials in hematology-oncology. It notes problems such as slow accrual, lack of good preclinical models and surrogate endpoints, and high false positive rates when relying on a single study with short follow-up. The document advocates considering alternative trial designs like adaptive randomization and enrichment to accelerate drug development while minimizing false results. It also stresses recognizing tumor heterogeneity and understanding biology to reduce false negatives and properly evaluate new agents.HCC: clinical update AASLD based
HCC Clinical update and hints from AASLD 2017 guidelines mainly about surveillance, diagnosis and treatment of Hepatocellular carcinoma in different stages.
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
This document discusses issues related to treating lymphoma in elderly patients. Key points include:
- Incidence of non-Hodgkin lymphoma (NHL) increases with age, while Hodgkin lymphoma has a bimodal distribution. Comorbid illnesses and medication tolerances are more common in elderly patients.
- Treatment options are more limited in elderly patients due to organ changes. Complete response rates and survival benefits of standard chemotherapy regimens can still be achieved in elderly patients, though toxicities must be carefully managed.
- Geriatric assessments prior to treatment help identify comorbidities, functional status, nutrition needs, and social support systems to optimize treatment planning and minimize toxicity risks in elderly lymphoma patients.
NUCs in Chronic Hepatitis B
HBV has been associated with humans for over 1,000 years. Recent evidence from a mummified Korean child who tested positive for HBV DNA establishes that HBV has been present in humans for at least 500 years. Treatment guidelines recommend antiviral therapy for patients with chronic HBV based on HBV DNA levels and ALT levels. Tenofovir and entecavir are preferred first-line treatments due to their superior efficacy, tolerability and low resistance profiles. Long-term antiviral therapy can reduce the risk of liver decompensation, hepatocellular carcinoma, and death in patients with chronic HBV.
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
"CML: What's New at EHA?", presented by Prof Tim Brümmendorf, EHA Patient Advocacy Capacity Building Session, EHA congress June 2017
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Similar to Powerpoint presentation by dr sathiha (20)
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Hepatocellul...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Hepatocellul...
Antibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute Panceriatitis
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...
LLA 2011 - B. Cheson - Problems of the design and interpretation of very earl...
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
More from zawhtet1984
Tanl power point
The study aimed to examine respiratory diseases in newborns, especially respiratory distress syndrome (RDS), and the relationship between gestational age, birth weight and RDS. It analyzed 30 newborns admitted to the neonatal intensive care unit and neonatal department from January to February 2008. The findings were that RDS predominantly affects preterm infants under 32 weeks gestation. Treatment for RDS included surfactant therapy, CPAP, ventilation and antibiotics. Combinations and durations of antibiotics depended on the diagnosis and severity of the condition.
Kyaw thura zaw
1) The document compares poly-chemotherapy (CVD regimen) and the same chemotherapy (CT) plus interferon-α2a in treating metastatic melanoma.
2) It studies 15 patients receiving either CVD alone or CVD plus interferon-α2a and finds the response rate was highest in the combined treatment group, though not significantly.
3) The median survival was 12 months for both groups, with the combined treatment group having a slightly higher average survival time.
Pyae phyo aung's thesis (breast cancer)
This study examined the significance of HER-2 and hormonal receptor status in patients with locally advanced breast cancer treated with neoadjuvant systemic therapy. It found that hormonal receptor status has a significant prognostic effect on both overall survival and progression-free survival. HER-2 receptor status was found to have a significant prognostic effect on overall survival. No significant association was found between receptor status and clinical response to neoadjuvant chemotherapy. The study was limited by its small sample size and retrospective design.
Zaw htet
1) This study analyzed prognostic factors that influence survival in patients with relapsed follicular lymphoma by examining clinical data from 151 patients.
2) Univariate analysis found that factors like older age, poorer performance status, advanced stage, short duration of response to initial therapy, and not achieving complete response were associated with worse survival.
3) Multivariate analysis identified that duration of response to initial therapy and performance status at relapse were the most important predictors of long-term survival, with patients having responses lasting 2+ years or good performance status having longer 5-year survival.
Sithu ko
The document analyzes the frequency and types of congenital heart diseases in newborns admitted to Tuschinskaya Children's Hospital from 2000 to 2009. It found that septal defects were the most common at 95.6% of cases, with atrial septal defects being the most frequent at 80.5%. The median frequency of congenital heart diseases in newborns each year was 4%. Patients were treated medically to address symptoms until they could undergo surgical treatment. A case study of a newborn with atrioventricular septal defect and patent ductus arteriosus requiring intensive care treatment is also described.
Khant zaw aung
This study compared the efficacy and toxicities of gemcitabine/cisplatin combination chemotherapy and paclitexal/carboplatin combination chemotherapy as first-line treatment for 53 patients with stage IIIB or IV non-small cell lung cancer. The study found that gemcitabine/cisplatin combination resulted in better response rates but not statistically significantly so. It also found that gemcitabine/cisplatin combination resulted in more hematological toxicities. Patient demographics were not significantly different between the two treatment arms. The study concluded that platinum-based combinations are effective for non-small cell lung cancer but require proper premedications.
Aung thiha soe
Lung cancer is a leading cause of cancer deaths worldwide. This retrospective study analyzed 95 patients with stage III-IV non-small cell lung cancer treated with first-line combination chemotherapy and second-line single-agent chemotherapy. The study found that the gemcitabine, platinum-based chemotherapy, and radiotherapy (GPR) regimen had a higher clinical response rate (21.3%) compared to other regimens. Leucopenia and fatigue were common toxicities for first-line treatment, while diarrhea was common for second-line treatment. The study concluded that while no regimen was statistically significantly better, GPR appeared to be more effective with acceptable toxicity.
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
The document discusses nutrition for preterm and congenitally small infants. It notes that preterm infants have high nutritional needs for optimal growth. Early minimal enteral feeding can provide advantages like faster weight gain and shorter hospital stays compared to parenteral nutrition alone. Breast milk is preferable to preterm formula due to beneficial components, though formula provides more calories, proteins and minerals. The study assessed the effectiveness of different nutrition methods in 30 preterm and small infants, finding that a combination of preterm formula and breast milk was most effective for growth.
Aung citt nyein
This study evaluated the efficacy and toxicity of a complex combination biochemotherapy regimen for 25 patients with advanced metastatic melanoma. A complete response was seen in 2 patients, partial response in 2 patients, and stable disease in 9 patients. The most common toxicities were lethargy, fever, nausea, vomiting, thrombocytopenia, leukopenia, and neutropenia. Doses of vindesine, cisplatin, and IL-2 often had to be reduced due to toxicities. The regimen showed an objective response rate of 16% with an 8% complete response rate, but dose reductions were frequently required due to treatment-related side effects.
More from zawhtet1984 (9)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Recently uploaded
The History of Stoke Newington Street Names
Presented at the Stoke Newington Literary Festival on 9th June 2024
www.StokeNewingtonHistory.com
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
How to Manage Your Lost Opportunities in Odoo 17 CRM
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
Pengantar Penggunaan Flutter - Dart programming language1.pptx
Pengantar Penggunaan Flutter - Dart programming language1.pptx
Walmart Business+ and Spark Good for Nonprofits.pdf
"Learn about all the ways Walmart supports nonprofit organizations.
You will hear from Liz Willett, the Head of Nonprofits, and hear about what Walmart is doing to help nonprofits, including Walmart Business and Spark Good. Walmart Business+ is a new offer for nonprofits that offers discounts and also streamlines nonprofits order and expense tracking, saving time and money.
The webinar may also give some examples on how nonprofits can best leverage Walmart Business+.
The event will cover the following::
Walmart Business + (https://business.walmart.com/plus) is a new shopping experience for nonprofits, schools, and local business customers that connects an exclusive online shopping experience to stores. Benefits include free delivery and shipping, a 'Spend Analytics” feature, special discounts, deals and tax-exempt shopping.
Special TechSoup offer for a free 180 days membership, and up to $150 in discounts on eligible orders.
Spark Good (walmart.com/sparkgood) is a charitable platform that enables nonprofits to receive donations directly from customers and associates.
Answers about how you can do more with Walmart!"
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)Academy of Science of South Africa
A workshop hosted by the South African Journal of Science aimed at postgraduate students and early career researchers with little or no experience in writing and publishing journal articles.Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...National Information Standards Organization (NISO)
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.The simplified electron and muon model, Oscillating Spacetime: The Foundation...
Discover the Simplified Electron and Muon Model: A New Wave-Based Approach to Understanding Particles delves into a groundbreaking theory that presents electrons and muons as rotating soliton waves within oscillating spacetime. Geared towards students, researchers, and science buffs, this book breaks down complex ideas into simple explanations. It covers topics such as electron waves, temporal dynamics, and the implications of this model on particle physics. With clear illustrations and easy-to-follow explanations, readers will gain a new outlook on the universe's fundamental nature.
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxMohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS Template 2023-2024 by: Irene S. Rueco
Recently uploaded (20)
Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Liberal Approach to the Study of Indian Politics.pdf
Liberal Approach to the Study of Indian Politics.pdf
How to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRM
Pengantar Penggunaan Flutter - Dart programming language1.pptx
Pengantar Penggunaan Flutter - Dart programming language1.pptx
Walmart Business+ and Spark Good for Nonprofits.pdf
Walmart Business+ and Spark Good for Nonprofits.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
Powerpoint presentation by dr sathiha
- 1. Standard BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease Moscow State University Faculty of Fundamental Medicine N.N.Blokhin Cancer Research Center Presented By : Dr .Sa Thi Ha (M.B;B.S) Supervisor : Prof Dr.B.I.Polyakov Dr.D.A.Bykov 17 th may 2010
- 14. 55 patients recruited 28 Assigned to BEACOPP 27 Assigned to COPP-ABVD 2 Excluded 2 did not have Hodgkin’s disease 2 Excluded 2 did not have Hodgkin’s disease 26 Eligible 1 lost to follow up 25 Elgible 1 lost to follow up 25 Included in the analysis 23 received full course 2 received partial course 24 Included in the analysis 20 received full course 4 received partial course Numbers of patients included in this analysis
- 16. Chacteristics of patients by stage
- 17. Acute Adverse Effects of Chemotherapy
- 18. Kaplan–Meier Analysis of the Probability of Freedom from Treatment Failure (Panel A) and Overall Survival (Panel B)
- 19. Rate of the early progression and Five year Kaplain-Meier estimates of the rate of free from treatment failure according to the International Prognostic Index. International Prognostic Index COPP-ABVD (%) Standard BEACOPP(%) Early progression Good (0-1) Fair (2-3) Poor (4-7) Freedom from treatment failure at 5 years Good (0-1) Fair (2-3) Poor (4-7) Overall survival at 5 years Good (0-1) Fair (2-3) Poor (4-7) 10 11 18 79 67 59 92 84 67 6 9 9 81 72 74 93 86 81
- 20. Outcome of Treatment and Five-Year Survival Rates. Variable COPP-ABVD (N=24) Standard BEACOPP (N=25) percent Complete remission 85(80-89) 88(85-91) Early progression 10(7-15) 8(5-10) Freedom from treatment failure at 5 yr 69(63-75) 76(72-80) Overall survival at 5 yr 83(78-87) 88(85-91)
- 23. Thank you for attention